ArticleFrontiers in oncology2022

CDCA4 as a novel molecular biomarker of poor prognosis in patients with lung adenocarcinoma.

Jianlong Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.